Literature DB >> 24784357

Return to play after acute infectious disease in football players.

Jürgen Scharhag1, Tim Meyer.   

Abstract

Acute infectious diseases are common in athletes and can impair their ability to train and to compete. Furthermore, continuing exercise during infectious diseases may lead to prolongation or aggravation of illness with severe acute or chronic organ manifestations. Therefore, even simple infectious diseases require a sufficient period of convalescence and recovery, during which exercise may be not allowed. Nowadays, especially in professional football with high pressures on players, staff and clubs due to broad public interests as well as financial constraints, the return-to-play decision is of utmost significance. Based on previous suggestions and our own experience within amateur and professional athletes and football players, this article aims to give a short overview on return-to-play decisions after common acute infectious diseases in football players.

Entities:  

Keywords:  football; infections; myocarditis; return to play; team physician; upper respiratory tract infection

Mesh:

Year:  2014        PMID: 24784357     DOI: 10.1080/02640414.2014.898861

Source DB:  PubMed          Journal:  J Sports Sci        ISSN: 0264-0414            Impact factor:   3.337


  4 in total

1.  Data from a nationwide registry on sports-related sudden cardiac deaths in Germany.

Authors:  Philipp Bohm; Jürgen Scharhag; Tim Meyer
Journal:  Eur J Prev Cardiol       Date:  2015-06-30       Impact factor: 7.804

2.  Upper Respiratory Tract Diseases in Athletes in Different Sports Disciplines.

Authors:  Anna Gałązka-Franta; Edyta Jura-Szołtys; Wojciech Smółka; Radosław Gawlik
Journal:  J Hum Kinet       Date:  2016-10-14       Impact factor: 2.193

Review 3.  The adolescent athlete's heart; A miniature adult or grown-up child?

Authors:  Guido E Pieles; A Graham Stuart
Journal:  Clin Cardiol       Date:  2020-07-09       Impact factor: 2.882

4.  Sport and exercise during and beyond the COVID-19 pandemic.

Authors:  Tee Joo Yeo
Journal:  Eur J Prev Cardiol       Date:  2020-06-15       Impact factor: 7.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.